Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
Royalty Pharma (Nasdaq: RPRX) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 11, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the conference call details and live webcast through the company's website investor relations section. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
Royalty Pharma (Nasdaq: RPRX) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per martedì 11 febbraio 2025, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà una conferenza telefonica e un webcast alle 8:30 ora orientale nello stesso giorno. Gli investitori possono accedere ai dettagli della conferenza telefonica e al webcast in diretta attraverso la sezione relazioni con gli investitori del sito web dell'azienda. Una registrazione sia della chiamata che del webcast rimarrà disponibile sul sito per un minimo di 30 giorni.
Royalty Pharma (Nasdaq: RPRX) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para martes 11 de febrero de 2025, antes de la apertura de los mercados en EE. UU. La empresa llevará a cabo una llamada de conferencia y un webcast a las 8:30 a.m. hora del este el mismo día. Los inversores pueden acceder a los detalles de la conferencia y el webcast en vivo a través de la sección de relaciones con inversores del sitio web de la empresa. Una repetición de la llamada y el webcast estará disponible en el sitio durante un mínimo de 30 días.
로열티 제약 (Nasdaq: RPRX)는 2025년 2월 11일 화요일 미국 시장이 열리기 전에 2024년 4분기 및 연간 재무 결과 발표 일정을 잡았습니다. 같은 날 동부 표준시 오전 8시 30분에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 투자자들은 회사 웹사이트의 투자자 관계 섹션을 통해 컨퍼런스 콜 세부정보 및 실시간 웹캐스트에 접근할 수 있습니다. 콜 및 웹캐스트의 재생은 최소 30일 동안 웹사이트에서 제공될 것입니다.
Royalty Pharma (Nasdaq: RPRX) a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour mardi 11 février 2025, avant l'ouverture des marchés américains. La société animera une conférence téléphonique et un webcast le même jour à 8h30, heure de l'Est. Les investisseurs peuvent accéder aux détails de la conférence téléphonique et au webcast en direct via la section relations investisseurs du site web de l'entreprise. Un enregistrement de la conférence et du webcast sera disponible sur le site pendant un minimum de 30 jours.
Royalty Pharma (Nasdaq: RPRX) hat die Bekanntgabe der Finanzresultate für das vierte Quartal und das gesamte Jahr 2024 für Dienstag, den 11. Februar 2025, vor der Öffnung der US-Märkte festgelegt. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten. Investoren können die Details zur Telefonkonferenz und den Live-Webcast über den Bereich für Investor Relations auf der Website des Unternehmens abrufen. Eine Aufzeichnung sowohl der Konferenz als auch des Webcasts wird mindestens 30 Tage lang auf der Website verfügbar sein.
- None.
- None.
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) release Q4 2024 earnings?
What time is Royalty Pharma's (RPRX) Q4 2024 earnings call?
How can investors access Royalty Pharma's (RPRX) Q4 2024 earnings call?
How long will Royalty Pharma's (RPRX) Q4 2024 earnings call replay be available?
